Adalimumab is associated with reduced risk of joint-related signs and symptoms compared with methotrexate in patients with moderate to severe psoriasis - 21/04/16
Doi : 10.1016/j.jaad.2016.02.924
Le texte complet de cet article est disponible en PDF.
Joseph Merola, Brigham & Women’s Hospital and Harvard Medical School, Boston, MA, United States; Murali Sundaram, AbbVie Inc, North Chicago, IL, United States; Min Yang, Analysis Group, Inc, Boston, MA, United States; Junlong Li, Analysis Group, Inc, Boston, MA, United States; Philip Galebach, Analysis Group, Inc, Boston, MA, United States; Martin Okun, Fort HealthCare, Fort Atkinson, WI, United States
Le texte complet de cet article est disponible en PDF.| Design, study conduct, and financial support for the study were provided by AbbVie; AbbVie participated in the interpretation of data, review, and approval of the abstract; all authors contributed to the development of the publication. |
© 2016
Publié par Elsevier Masson SAS.
Vol 74 - N° 5S1
P. AB235 - mai 2016 Retour au numéro
Article précédent
- Adalimumab dose escalation, deescalation, and reescalation in patients in the REVEAL study
- Adalimumab significantly improves PASI scores in head region among patients with moderate-to-severe psoriasis: Analysis from REVEAL and CHAMPION
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?